Paracetamol, when contained in rectal suppositories. (S0, S1)
Pentoxyfylline
Phenazone (antipyrone).
Phenazopyridine.
Phenylpropanolamine, preparations and mixtures where the recommended daily dose for adults does
not exceed 100 milligrams and for children 6 to 12 years, does not exceed 50 milligrams, when intended
for the symptomatic relief of nasal and sinus congestion.
Pholcodine; preparations and mixtures when compounded with one or more therapeutically active
substances and containing 20 milligrams or less of pholcodeine (calculated as base) per dosage unit
and liquid oral preparations and mixtures containing 20 milligrams or less of pholcodeine (calculated as
base) per 5 millilitre dosage unit. (S6)
Pholedrine.
Pinaverium.
Pipenzolate.
Pipoxolan.
Pirbuterol, except when contained in respirator solutions. (S3)
Piroxicam, when intended for the emergency treatment of acute gout attacks and when intended for the
treatment of post traumatic conditions such as pain, swelling and inflammation, for a maximum period of
5 days. (S3)
Pizotifen; preparations and mixtures, when intended for prophylaxis of migraine. (S5)
Podophyllum resin; preparations and mixtures containing 20 percent or less thereof. (S4)
Poldine methylsulphate.
Polyvalent snake antivenom.
Potassium chloride, where the recommended dose is more than 20 millimol of potassium (1500
milligrams of potassium chloride) per 24 hours or when intended for intravenous infusion or for injection,
but except when contained in oral rehydration preparations. (S0)
Prifinium bromide.
Procaterol, except when contained in respirator solutions. (S3)
Procyclidine.
Proglumide.
Promethazine; preparations and mixtures when intended for use as an antihistamine, for application to
the skin and when intended specifically for the treatment of travel sickness. (S5)
Propantheline bromide.
Propyphenazone.
Proxymetacaine, when contained in eye drops intended for emergency treatment of arc eyes. (S4)
Quinine; preparations and mixtures containing more than 1,0 percent thereof.
Ranitidine, when administered orally for short-term symptomatic relief of heartburn and hyperacidity,
subject to—
(a)
a maximum dose of 75 milligrams;
(b)
a daily dose of 300 milligrams;
(c)
a maximum treatment period of two weeks. (S3)
Reproterol, except when contained in respirator solutions. (S3)
Rimiterol, except when contained in respirator solutions (S3) and except when intended for injection.
(S4)
Sabadilla alkaloids; substances, preparations and mixtures containing 1,0 percent or more thereof.
Salbutamol, except when contained in respirator solutions (S3) and except when intended for injection.
(S4)
Salmefamol, except when contained in respirator solutions (S3) and except when intended for injection.
(S4)
Salmeterol.
Siccanin, when intended for application to the skin.
Silver sulphadiazine, when intended for application to the skin in the short-term treatment of minor
bums, provided that the pack size is limited to a maximum of 50 grams. (S4)
Sodium cromoglycate, except when intended for veterinary use. (S4)
Strychnine; preparations and mixtures containing 0,2 percent or less thereof, except the substance. (S4)
Sulphonamides, when intended for application to the eyes, nares and vagina, (S4), except when
registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock
Remedies Act, 1947 (Act No. 36 of 1947).
Terbutaline, except when contained in respirator solutions. (S3)
Tetracaine, when contained in eye drops intended for emergency treatment of arc eyes. (S4)
Theophylline and its derivatives, unless listed in another Schedule, except preparations for injection.
(S4)
Tiaprofenic acid, when intended for the treatment of post traumatic conditions such as pain, swelling and
inflammation, for a maximum period of 5 days. (S3)
Timepidium.
Tiotropium.
Triamcinolone, when intended for application to oral lesions. (S4)